Point Biomedical Report issue

For profit Phase 3
Founded: San Carlos CA United States (1996)
Status: Defunct (2008)

Organization Overview

First Clinical Trial
2002
NCT00594698
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Alternative names

POINT Biomedical Corp.

Active Ingredients

Drugs in Phase 3 Trials (1)

Lyophilisate (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Myocardial Ischemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 1